There is no assurance that this process will result in the completion of any specific transaction or outcome.

Our lead program and current focus is on the development of the fixed dose combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor ...

The Kirby Institute Viral Immunology Systems Program, Faculty of Medicine, The University of New South Wales, Sydney, Australia School of Biomedical Sciences Viral Immunology Systems Program, Faculty ...

Overall, 38/51 (75%) were cured with first-line treatment (mean duration 37 days). Despite a high prevalence of putative NS5A-inhibitor resistance-associated substitutions (RASs), all first-line ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...